The aim of this study is to investigate the role of single-nucleotide polymorphisms (SNPs) of the glucocorticoid receptor (GR) and of the related co-chaperone FKBP5 genes in the development of glucocorticoid (GC) resistance in Crohn's disease (CD) and ulcerative colitis (UC) patients. We have developed a high-resolution DNA melting method that allows simultaneous identification of GR (BclI, N363S and ER22/23EK) and FKBP5 (rs3800373, rs1360780 and rs4713916) polymorphisms. Genotype frequencies were determined in 100 consecutive CD and 100 UC patients under GCs therapy (50 responders and 50 resisters). The variation of FKBP5 polymorphism rs4713916 (G/A), in the putative promoter region of FKBP5, is significantly associated with resistance to GC treatment in CD (responder ¼ 17% versus resister ¼ 35%; P ¼ 0.0043). No significant differences were found in UC patients. If these preliminary findings will be confirmed, the combination of GR and FKBP5 mutational analyses could help to identify subgroups of CD patients with higher chances to benefit from GC treatment.
Introduction
Glucocorticoids (GC) are potent inhibitors of T-cell activation and proinflammatory cytokines, and are largely considered highly effective treatment for active inflammatory bowel disease (IBD). Nonetheless, about 30% of patients with ulcerative colitis (UC) and Crohn's disease (CD) have a poor or absent clinical response to steroids and reduced responses of circulating lymphocytes to GC. GC resistance, and often steroid dependence, significantly increase the need for surgery in IBD. Moreover, although the anti-inflammatory effect of GC is blunted or absent, GC-resistant patients are still at risk from side effects. The finding that GC resistance occurs along with GC side effects provides an important hint to the molecular mechanism of resistance. 1, 2 Although the molecular basis of GC resistance has been widely assessed in other inflammatory conditions, GC refractoriness in IBD patients is still poorly understood. Common mechanisms of resistance are (i) decreased cytoplasmic GC concentration, secondary to increased P-glycoprotein-mediated efflux of GC from target cells; (ii) constitutive epithelial activation of pro-inflammatory mediators, including mitogen-activated protein kinases, nuclear factor-kB and activator protein-1, resulting in inhibition of GC receptor (GR) transcriptional activity; and (iii) impaired GC signaling due to dysfunctions at the level of GR. With regard to the latter, a large number of studies on T lymphocytes and other target inflammatory cells support the role of GR abnormalities in the onset of GC resistance. The GR exists in two major isoforms, GRa and GRb, generated by alternative mRNA splicing. GRa can be activated by glucocorticoid ligands, whereas GRb has not been shown to bind glucocorticoids. Although GR abundance and tissue distribution seem not to be relevant, several researches have pointed to the differential expression of the regulatory GRb subunit as a mechanism of decreased GR sensitivity. 1, 3 In this regard, the molecular mechanism of steroid resistance in New World primates, such as squirrel monkeys (Saimiri scireus), provides additional indications. GR exists as an intracellular complex with the chaperones HSP90 and HSP70, and several co-chaperones as the immunophilins FK506-binding proteins FKBP51 and FKBP52. This machinery ensures that GR are properly folded, and regulate competence of the cytosolic GR as a ligand-induced transcription factor. [4] [5] [6] It has been found that an increase in the levels of FKBP51 contributes to GC resistance in New World primates: this protein causes an up to 11-fold reduction of the GR affinity for corticosteroids, and is expressed at a level about 13-fold higher than in humans. 7 Although less potent than squirrel monkey FKBP51, human FKBP51 can also modify steroid receptor activity and regulate steroid responsiveness. It has been proposed that GC resistance develops from a lower hormone binding affinity by the transcriptional subunit GRa, caused by the interaction with FKBP51, and this leads to a reduced nuclear translocation and activation of GRa itself. 8 Concomitantly, GRb and FKBP51 inhibit GRa activity through an additional mechanism, involving FKBP51-mediated enhancement of GRb nuclear translocation. 3 GR activity is crucial not only for the regulation of the inflammatory response, but also for its negative feedback action on the activation of the hypothalamuspituitary-adrenal axis. Proper GR function is demonstrated to be critical for a healthy stress response, whereas excessive activation of this system is implicated in the pathogenesis of mood and anxiety disorders. [9] [10] [11] [12] In this regard, a number of single-nucleotide polymorphisms (SNPs) of the GR gene (5q31-32) and of the FKBP51 gene (FKBP5) (6p21.3-21.2) have been indicated as risk factors for stress-related psychiatric disorders and have been associated with altered response to antidepressant drugs.
11,13-15 Several well-described polymorphisms within GR gene have been already associated to various diseases and are suspected to contribute to impaired response to GC therapy. In particular, lower cortisol responses have been observed in subjects homozygous for the BclI variant (no rs number), which is a restriction fragment-length polymorphism located in the first intron of GR; 16 carriers of the exonic N363S variant (rs 6195), resulting in an asparagine to serine amino acid exchange of the GR protein, have shown an increased cortisol response to psychosocial stress, 16, 17 whereas the ER22/23EK (rs6189 and rs6190) polymorphism is associated with a better metabolic profile because of the relative resistance to GC. This was also confirmed by a follow-up study demonstrating an increased survival rate in elderly male carriers of the ER22/23EK polymorphism compared with non-carriers. 18 On the other hand, the FKBP5 SNPs rs3800373, rs1360780 and rs4713916 were found to upregulate protein levels, to increase recurrence of depression, and to affect response to stress tests and antidepressant treatment. 19 Given the functional role of FKBP51, SNPs within the FKBP5 gene might affect protein expression, and are therefore likely to take part in the development of interindividual differences with respect to sensitivity to GC pharmacological treatment. Indeed, FKBP51 mRNA expression levels in peripheral blood mononuclear cells have been used to assay individual responsiveness to corticosteroids. 20 In addition, Woodruff et al. 21 identified FKBP51 as a biomarker of corticosteroid responsiveness and a potential mediator of corticosteroid-resistant asthma.
Despite the proven importance of FKBP51 expression for GC action in a number of different tissues, no evidence is available, to our knowledge, of an association between the three FKBP5 SNPs and interindividual diversity in GC response in IBD, which was therefore evaluated in this study.
Materials and methods

Study population
Patients affected by IBD were consecutively recruited at IRCCS-'Casa Sollievo della Sofferenza' Hospital in San Giovanni Rotondo, Italy. Diagnosis of CD and UC was established according to accepted clinical, endoscopic, radiological and histological criteria. 22 A detailed clinical questionnaire, concerning different features of the disease, was used according to the Montreal classification. 23 Detailed phenotypic data were available for members of this cohort, concerning the family history of IBD, presence of one or more extra-intestinal manifestations, and previous bowel resection ( Table 1 ). All subjects signed a written agreement; the study was approved by the local ethics committees. On the basis of medical records, patients under corticosteroid treatment were classified as responders or resisters, according to accepted criteria. 24 More specifically, steroidresistant IBD (CD or UC) is defined as the active disease in spite of an adequate dose and duration of prednisone therapy (0.75-1 mg kg À1 per day or equivalent for at least 2 weeks). Conversely, patients were classified as responders when a clinical response was achieved after 2 weeks and remission within 4-8 weeks.
Genomic DNA was successfully extracted from 100 CD and 100 UC Caucasian patients. In all, 50 patients were responders to GC and 50 patients were resistant to GC in each group of CD and UC patients. Demographic features of CD and UC patients are shown in Table 1 . DNA extraction was performed at IRCCS-'Casa Sollievo della Sofferenza' Hospital, and SNPs analyses were performed at the Department of Biomolecular Sciences of the University of Urbino, Italy, in the second semester of 2010.
Validation of FKBP5 SNPs assay
Genomic DNA was extracted from 35 Caucasian healthy subjects. The control samples belong to a collection of healthy subjects, randomly selected, that were already used in various studies from our laboratory. PCR reactions, cycling and high-resolution melt (HRM) analyses, specifically designed for the allelic discrimination of all SNPs in a single run on the Rotor-Gene 6000TM (Corbett Research, Mortlake, New South Wales, Australia), were performed as described below. Controls were used in order to validate the method comparing the results obtained by HRM with those obtained through pyrosequencing performed on the PyroMark ID system (Biotage AB, Uppsala, Sweden). The w 2 -statistics were used to test differences in genotype frequencies between cases and controls. Hardy-Weinberg equilibrium for SNPs in FKBP5 gene was assessed using the online software 'Hardy-Weinberg equilibrium calculator' (http://www.oege.org/software/hardy-weinberg.shtml). HRM analysis enables the distinction of homozygous wild-type, homozygous mutant and heterozygous mutant genotypes, as it is shown for the rs3800373, rs1360780 and rs4713916 mutations (See Supplementary Figures 1-3 ). This technique was used here to develop a method for the simultaneous genotyping of BclI, N363S, ER22/23EK polymorphisms located within the GR gene, 25 and of rs3800373, rs1360780 and rs4713916 polymorphisms located within FKBP5 gene using the same reaction mixture (data not shown). Thus, our system enables the simultaneous detection of six different polymorphisms related to the response to GCs. As for the validation of our method, we found an exact concordance between HRM and pyrosequencing results for all the 35 control samples used. All FKBP5 SNPs were found to be in Hardy-Weinberg equilibrium (data not shown). Note that some data are missing. Demographic data from three UC (resister) patients were not available.
SNPs and glucocorticoid response in IBD patients P Maltese et al Genotyping Genomic DNA was extracted from at least 200 ml of whole blood using the 'salting out' method. 26 PCR primers were designed by Diatheva (Diatheva S.r.l., Fano, Italy) according to the same parameters previously described for GR polymorphisms, 25 avoiding hairpins and primer-dimer formation and maintaining the amplicon length within the 80-150 bp range. Assembly of PCR reactions, cycling and HRM analyses, specifically designed for the allelic discrimination of all SNPs in a single run on the Rotor-Gene 6000TM were performed as described elsewhere. 25 Briefly, the reaction mixture contained 10 ng of genomic DNA,
Statistical analyses
The w 2 statistics were used to test differences in genotype frequencies between responders and resisters to GC therapy. The odds ratio was used to estimate the response to GC therapy in those subjects with minor allele frequency in the genetic profile. All statistics were performed using MedCalc (MedCalc, Mariakerke, Belgium). Haploview software version 4.2 (http://www.broadinstitute.org/haploview/ haploview) was used to perform haplotype analyses, and the w 2 -test was used to compare the haplotype frequencies of GC responder and resister sub-populations. Subjects with missing data, due to genotyping failure of as little as one polymorphism, were excluded from the haplotype analyses. P-values o0.05 were considered significant.
Results
Analyses were carried out both in CD and UC patients, with respect to the outcome of therapy in terms of response and resistance to corticosteroids. The genotyping results of individuals were of adequate quality for all the CD but not for all the UC patients; accordingly, allele frequencies and haplotypes have been analyzed on 50 resister/50 responder CD patients and on at least 45 resister (90% of patients enrolled)/46 responder (92% of patients enrolled) UC patients. In Tables 2 and 3 , we identified the risk allele of each GR and FKBP5 SNP investigated within the IBD cohort under study. By evaluating the risk allele frequencies and patient distribution, we found that the rs4713916 risk allele 'A' is differently distributed between the responder (17%) and resister (35%) CD populations (P ¼ 0.0043; Table 2 ). Genotype distribution and odds ratio estimation reveal a strong association to GC response of the rs4713916 genotypes containing at least one 'A' allele in CD patients (GA/AA, odds ratio ¼ 3.81, confidence interval ¼ 1.66-8.75, P ¼ 0.0016; Table 2 ), whereas no significant associations where observed in UC patients ( Table 3 ). The three GR and three FKBP5 variants were included in the haplotype calculations using the Haploview software. Three haplotypes were predicted to exist in both the CD and UC studied cohorts for the three GR SNPs and five for the three FKBP5 SNPs. Of these eight haplotypes, six occur at a frequency higher than 4% in CD patients (Table 4) , whereas only five Table 1 ). Analysis of haplotype distribution confirms that only in the presence of rs4713916 risk allele 'A' does a significant difference (Po0.05) exist between responder and resister CD patients (Table 4) . No significant differences were found in the haplotype distribution of UC patients (Supplementary Table 1 ). In addition, analysis of CD clinical features revealed that colonic localization is predominant in the resister patients (42%) compared with the responders (14%; Po0.0001) (data not shown).
Discussion
The study of IBD from a pharmacogenetic point of view is particularly interesting in light of the fact that GC, which represent a frequent treatment for such diseases, are well known to induce serious side effects, as well as to generate dependence and resistance in patients undergoing this type of therapy. In this study, SNPs of genes involved in the response to GC were taken into consideration, and six in total were selected among the most intriguing located on both the GR gene and the gene coding for the accessory protein with inhibitory function, FKBP5.
The study of the three polymorphisms in the FKBP5 gene (rs3800373, rs1360780 and rs4713916) indicates that, for the rs4713916 SNP, a strong correlation exists between the presence of the 'A' allele and responsiveness to therapy in CD patients (Table 2 ). This evidence is confirmed by risk analysis on patients heterozygous or homozygous for the minor allele frequency polymorphism, suggesting that the likelihood of showing GC resistance is up to four times higher in carriers of the G/A and A/A genotype compared with carriers of the G/G genotype (odds ratio ¼ 3.81, Table 2 ). Results from the haplotype analyses indicate two risk haplotypes, both bearing the 'A' allele of the SNP rs4713916: G-T-A (rs3800373-rs1360780-rs4713916), which is present in 26% of GC resister patients and in 14% of responder patients (P ¼ 0.03), and T-C-A, in 7% of resister patients and in 1% of GC responder patients (P ¼ 0.03). The T-C-G haplotype shows an opposite trend, as it is distributed more frequently, although not significantly (P ¼ 0.06), in the group of GC responders (73%) than in GC resister (60%), providing further evidence of the association between the presence of the 'A' allele and GC resistance (Table 4 ).
In conclusion, the data shown here for the FKBP5 polymorphisms are definitely more meaningful with respect to the hypothesis of this study, that is, that the FKBP5 polymorphisms, selected on the basis of their association with response to antidepressants, with cases of psychosis, with regulation of the hypothalamus-pituitary-adrenal axis and of the stress response, might have a role in the responsiveness to synthetic GC. In fact, although the exact mechanism underlying GC resistance needs further investigation, a likely model is represented by the impaired negative feedback of the anti-inflammatory response. Our results indicate that the rs4713916 polymorphism, located in the promoter region of the FKBP5 gene, is likely to influence the expression of this inhibitory co-chaperone, and we demonstrate indeed that it favors resistance to GC. Further studies will be required to determine how the FKBP5 SNPs affect expression levels of the protein. Nonetheless, our conclusions are strengthened by an increasing number of studies underlining the relevance of these SNPs in hormonal regulation.
It is intriguing to note the lack of association between FKBP5 polymorphisms and GC response in UC patients (Table 3 and Supplementary Table 1 ). It must be stressed that, despite IBD having some common physiopathological features, UC and CD are actually two different diseases, whose etiology is as yet unclear, as are the mechanisms of response to therapeutic agents. Indeed, the lack of association observed may be possibly explained by the distinct localization of the two diseases: as shown in the demographic tables (Table 1) , the site of inflammation in GC resister patients is mainly the colon (21/50 resister CD patients and 34/47 resister UC patients), in contrast to what happens in GC-sensitive subjects (7/50 responder CD patients and 17/50 responder UC patients). Moreover, GC resistance, actually, the colonic involvement in both CD and UC, appears to be associated with an increased rate of indication for surgery (Table 1 ). In accordance with our results, some studies, including the large multicenter European Cooperative Crohn's Disease Study and National Cooperative Crohn's Disease Study, have shown that the anatomical localization influences the overall course of disease. Colonic involvement and especially diseases confined to the colon only, cause a worse overall outcome and more severe disease in CD patients. [27] [28] [29] [30] With respect to treatment outcome, the National Cooperative Crohn's Disease Study found that the GC analog prednisone is efficacious on CD patients with ileal or ileal-colonic disease, but the drug is not better than placebo when the disease exclusively involves the colon. 27 The reason for such a colon resistance link remains unclear; nonetheless, it could explain why we did not observe any association between the rs4713916 polymorphism and response to therapy in UC.
In conclusion, this work has demonstrated the association between the rs4713916 polymorphism of the FKBP5 gene and GC response in CD. Our data are consistent with those of a meta-analysis performed on patients with mood disorders, in which it was demonstrated that treatment response is associated with FKBP5 gene polymorphism rs4713916, but not with rs3800373 or rs1360780. 31 Similarly, Hawkins et al. 32 demonstrated lack of association between rs3800373 and GC response in asthmatic subjects.
Hence, this makes rs4713916 a likely predictive genetic biomarker useful in the evaluation of the proper therapeutic response to GC for this disease. However, more studies are needed, as possible limitations of this study are the size of sample investigated and the retrospective evaluation of response to GC. Nonetheless, a more widespread application of pharmacogenetic and identified genetic biomarkers will enable early stage intervention, before debilitating and recurrent symptoms of the disease take place, and this will have a long-term impact in terms of morbidity and mortality, also ensuring a targeted treatment, using reliable drugs while avoiding those that are unnecessary or even harmful.
Finally, worth mentioning is the technique used here for the identification of the SNPs. HRM analysis is based on the evidence that changes in the nucleotide sequence lead to changes in thermal stability, that affect denaturing temperature and melting profile of an amplicon. 33 This analysis provides an effective screening method and is an important step ahead in the simplification of those techniques used until now for the identification of genetic biomarkers. The main limitation of HRM is that it cannot exactly characterize the mutation, which implies that a sequencing method should be used in conjunction with HRM analysis. However, sequencing is normally required only during the validation step of the HRM method. Moreover, HRM is, as yet, affected by low resolution, limiting, in particular, discrimination of homozygous mutants from homozygous wild-type samples, as we have previously described. 25 Nonetheless, HRM analysis avoids the excessive sample handling, long times and high costs of other techniques. In addition, considering the bioinformatics component of this technique, it is likely that future implementation will make the HRM analysis an even more powerful method.
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